Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC410, FOLFIRINOX, and Nivolumab +/- Ipilimumab in Treatment-naïve Metastatic Pancreatic Cancer
NCT06941857Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of NC410 in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Number of participants experiencing unexpected toxicities at 4 years. Started Sep 2025; status: recruiting.
02
Drugs
NC410
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06941857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941857.